Advertisement

Search Results

Advertisement



Your search for Hope matches 3185 pages

Showing 51 - 100


prostate cancer

AACR Statement on Former President Joseph Biden’s Cancer Diagnosis

The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...

gynecologic cancers

I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer

More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...

prostate cancer

Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals

The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...

skin cancer
genomics/genetics
immunotherapy

Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma

Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...

breast cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...

issues in oncology

Are Most Americans Aware of the Link Between Alcohol and Cancer Risk?

Although alcohol consumption is a known leading preventable cause of cancer, public awareness of the connection may remain concerningly low in the United States, according to a recent study published by Domgue et al in JAMA Oncology. Background Consuming alcohol has been linked to at least seven...

lung cancer

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...

issues in oncology

ASCO 2025: Alcohol-Related Cancer Deaths Are on the Rise in the United States

A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings were presented at the 2025 ASCO Annual Meeting (Abstract ...

leukemia

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy

With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...

skin cancer
genomics/genetics

Use of Niraparib in Patients With Advanced Melanoma

Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology. Background The U.S. Food and Drug...

lung cancer

I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World

Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...

integrative oncology
palliative care

Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice

Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James

Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....

issues in oncology

The Power of Translational Science to Transform the Lives of Patients Worldwide

Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...

colorectal cancer

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...

palliative care

AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer

FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer.   The study demonstrated that FaceAge could...

Overall Survival Analysis in CodeBreaK 300: Sotorasib Plus Panitumumab vs Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer

As reported in the Journal of Clinical Oncology by Pietrantonio et al, overall survival analysis in the phase III CodeBreaK 300 trial showed numeric improvement with sotorasib/panitumumab vs investigator's choice of treatment in patients with chemorefractory KRAS G12C-mutant metastatic colorectal...

multiple myeloma

How Could So Many Physicians Have Failed Me?

The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director of Clinical Cancer Research and the ...

leukemia

ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia

The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...

leukemia

AML: MRD Testing Led to Survival Benefits in Subset of Patients

Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology.   Patients with both mutations...

colorectal cancer

Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer

Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology.   The 5-year mortality rate in patients with a...

thyroid cancer

AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers

A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...

gastrointestinal cancer
genomics/genetics

DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes

Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...

leukemia

AACR 2025: Using Single-Cell RNA Sequencing to Evaluate Cell States in AML

A new gene-expression atlas developed using single-cell RNA sequencing data sheds light on how normal hematopoietic cells differentiate and was used to catalog the multiple ways aberrant differentiation can lead to acute myeloid leukemia (AML). Andy G.X. Zeng, PhD, an MD/PhD candidate at the...

solid tumors
genomics/genetics

AACR 2025: Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy

According to the results of a molecularly matched, tumor-agnostic phase II trial, the combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab demonstrated antitumor activity with no new safety signals, particularly in patients with BRCA1/2 mutations. Data from this...

sarcoma
issues in oncology

AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients

A novel artificial intelligence (AI)-based model could accurately classify sarcomas among pediatric patients using digital pathology images alone, according to new findings presented by Thiesen et al at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 2423/8)....

skin cancer
issues in oncology

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...

solid tumors
hematologic malignancies
issues in oncology
immunotherapy
survivorship

Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), accepted the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine...

immunotherapy

AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors

PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient (dMMR) cancers, according to preliminary results from a phase II trial presented at the 2025 American Association...

colorectal cancer
issues in oncology

Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer

Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute

Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....

issues in oncology

ASCO Updates Guideline for Fertility Preservation in People With Cancer

ASCO has released an update to the guideline for fertility preservation in people with cancer. The update, recently published in the Journal of Clinical Oncology,1 provides recommendations regarding evaluation and counseling for fertility preservation; methods and timing of fertility preservation;...

solid tumors
immunotherapy

Response to Immune Checkpoint Inhibitors Not Affected by Age

Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...

breast cancer

Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, FASCO, to Lead Women’s Cancers Program at City of Hope

Hope S. Rugo, MD, FASCO, recently joined the staff of City of Hope as the new Director of the Women’s Cancers Program, Division Chief of Breast Medical Oncology, and Professor in the Department of Medical Oncology and Therapeutics Research. In her role, she will lead and enhance City of Hope’s...

hepatobiliary cancer
issues in oncology

Novel Drug/Device Combination May Improve Outcomes in Metastatic Uveal Melanoma

Percutaneous hepatic perfusion using a melphalan hepatic delivery system (melphalan/HDS) may be an effective treatment option in patients with unresectable uveal melanoma that has metastasized to the liver, according to a recent study published by Zager et al in the Annals of Surgical Oncology....

issues in oncology

Link Between CT Scans and Future Cancer Incidence?

At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...

cns cancers
skin cancer
lung cancer
immunotherapy

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...

issues in oncology
health-care policy

Crossing State Borders: Addressing Residential Barriers to Cancer Care

A high proportion of Medicare beneficiaries cross state borders to access cancer care, particularly patients residing in rural areas, according to a recent study published by Moen et al in JAMA Network Open. The findings have significant implications for telehealth policies and physician licensure, ...

lymphoma
immunotherapy

NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma

A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...

hematologic malignancies
issues in oncology

Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis

A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...

breast cancer

Breast Shrinkage Following Breast-Conserving Therapy

Breast-conserving therapy, including radiation therapy, could lead to a progressive reduction in breast size over time among women with early-stage breast cancer, according to a recent study published by Becker et al in Plastic and Reconstructive Surgery. Background Breast-conserving...

palliative care

Bringing Palliative Care to Every Patient With Cancer

Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...

pancreatic cancer
issues in oncology
genomics/genetics
immunotherapy

Race-Associated Molecular Differences and Treatment Response in Pancreatic Cancer

Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...

head and neck cancer
immunotherapy

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...

lung cancer
issues in oncology
genomics/genetics

Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC

Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...

issues in oncology

Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...

cns cancers

Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma

The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...

ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor

In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...

issues in oncology
solid tumors

Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality

Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...

Advertisement

Advertisement




Advertisement